This trial is investigating whether using high doses of focused radiation (SBRT) to treat oligo-progression (a subset of cancer cells that develop heterogeneity and resistant clones while receiving systemic therapy) is effective.
- Metastatic Breast Cancer
3 Primary · 0 Secondary · Reporting Duration: 24 month period
Side Effects for
3 Treatment Groups
1 of 3
Oligo-metastatic Breast Cancer
1 of 3
1 of 3
100 Total Participants · 3 Treatment Groups
Primary Treatment: Stereotactic Body Radiotherapy · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there still opportunities for patients to register in this trial?
"Affirmative. Clinicaltrials.gov's records demonstrate that, from 9/11/2019 to 10/6/2022, this clinical trial is actively recruiting 80 participants at a single site." - Anonymous Online Contributor
How many individuals are being recruited to participate in this research?
"Affirmative. According to the information sourced from clinicaltrials.gov, this trial is recruiting participants and was first posted on September 11th 2019 with its most recent update occurring October 6th 2022. 80 patients must be enrolled at a single location for the study to proceed." - Anonymous Online Contributor